$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What are the possible drug reactions when using crizotinib targeted drugs?
2026-02-01 22:25:32
Check Details
The therapeutic effect of crizotinib on significant tumor shrinkage in patients with advanced lung cancer
2026-02-01 22:25:32
Check Details
Is crizotinib useful in treating advanced lung cancer?
2026-02-01 22:25:32
Check Details
How long does it take for drug resistance to crizotinib to develop
2026-02-01 22:25:32
Check Details
Study on the therapeutic effect of crizotinib on MET gene mutations
2026-02-01 22:25:32
Check Details
How effective is crizotinib in treating lymphatic metastasis?
2026-02-01 22:25:32
Check Details
Is ivonib a targeted drug? Detailed explanation of its mechanism of action and indications
2026-02-01 22:25:32
Check Details
Detailed explanation of the mechanism of action, efficacy and applicable symptoms of ivonib
2026-02-01 22:25:32
Check Details
Ivonib: Medication guide for patients with IDH1-mutated AML
2026-02-01 22:25:32
Check Details
Will olaparib develop resistance? How to deal with drug resistance?
2026-02-01 22:25:32
Check Details
Does Lynparza need to be taken long-term?
2026-02-01 22:25:32
Check Details
Efficacy of olaparib in treating BRCA mutated cancers
2026-02-01 22:25:32
Check Details
1
2
...
1084
1085
1086
1087
1088
1089
1090
...
10238
10239
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
2
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
3
Eltrombopag: TPO-Receptor Agonist in ITP and Severe Aplastic Anemia
4
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure
5
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
6
Vosoritide Slowing Effect: Not Always Resistance—Check Dose, Adherence, Epiphyses
7
Ramosetron ODT for IBS-D: Gender-Based Dosing and Treatment Review
8
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
9
Acoramidis for ATTR-CM: TTR Stabilizer to Reduce CV Death and Hospitalization
10
Vosoritide Storage and Reconstitution: Refrigerate, 90-Day Room Temp, Use Within 3 Hours
11
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
12
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity